Patents Examined by Padma Baskar
  • Tissue cement proteins from
    Patent number: 7335733
    Abstract: The present invention relates to tissue cement proteins produced by certain species of blood-feeding ectoparasites. These proteins and compositions comprising these proteins are particularly useful for the temporary or permanent bonding of animal tissues to each other or to other biomaterials. The present invention also relates to the use of tissue cement proteins in the production of vaccines that protect animals against the bite of blood-sucking ectoparasites and the transmission of viruses, bacteria and other pathogens by such ectoparasites.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: February 26, 2008
    Assignee: Merial Limited
    Inventors: Guido Christian Paesen, Patricia Ann Nuttall
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7335493
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: February 26, 2008
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7335494
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: February 26, 2008
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • antigens and corresponding DNA fragments and uses thereof
    Patent number: 7335370
    Abstract: The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: February 26, 2008
    Assignee: Aventis Pasteur Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
  • 28 kDa outer membrane protein multigene family
    Patent number: 7332171
    Abstract: The 28-kDa outer membrane proteins (P28) of Ehrlichia chaffeensis are encoded by a multigene family consisting of 21 members located in a 23-kb DNA fragment in the genome of E. chaffeensis. Fifteen of these proteins are claimed herein as novel sequences. The amino acid sequence identity of the various P28 proteins was 20-83%. Six of 10 tested p28 genes were actively transcribed in cell culture grown E. chaffeensis. RT-PCR also indicated that each of the p28 genes was monocistronic. These results suggest that the p28 genes are active genes and encode polymorphic forms of the P28 proteins. The P28s were also divergent among different isolates of E. chaffeensis. The large repertoire of the p28 genes in a single ehrlichial organism and antigenic diversity of the P28 among the isolates of E. chaffeensis suggest that the P28s may be involved in immune avoidance.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: February 19, 2008
    Assignee: Research Development Foundation
    Inventors: David H. Walker, Xue-Jie Yu
  • Assays for detection of
    Patent number: 7329738
    Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: February 12, 2008
    Assignee: Biosite Incorporated
    Inventors: Bruce Andrew Lee, Becky Mar Flores, Gunars Edwin Valkirs
  • Gene encoding protein from merozoite of , recombinant protein obtained with said gene and use thereof
    Patent number: 7326543
    Abstract: The present invention provides a gene encoding a protein from merozoite of Babesia caballi, a recombinant protein of Babesia caballi, and an antibody capable specifically binding to a 48 kDa protein of rhoptry of Babesia caballi merozoite. In accordance with the present invention, it is possible to stably prepare the 48 kDa protein of rhoptry of Babesia caballi and the gene encoding said protein in a large amount with the recombinant DNA technique. The present invention also provides a method for diagnosing equine babesiasis which comprises either specifically detecting anti-Babesia caballi antibody present in equine blood by using the recombinant protein of present invention as an antigen or detecting the presence of Babesia caballi merozoite in equine blood by using the antibody of the present invention.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: February 5, 2008
    Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Hiromi Ikadai, Ikuo Igarashi, Naoyoshi Suzuki, Hideyuki Nagasawa, Kozo Fujisaki, Takeshi Mikami
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7326544
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: February 5, 2008
    Assignee: sanofi pasteur limited
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • antigens and corresponding DNA fragments and uses thereof
    Patent number: 7326545
    Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: February 5, 2008
    Assignee: Sanofi Pasteur Limited
    Inventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
  • protein, gene sequence and uses thereof
    Patent number: 7311917
    Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: December 25, 2007
    Assignee: Emergent Product Development Gaithersburg, Inc.
    Inventors: Kenneth Tucker, Ulrich F. Tillmann
  • Recombinant merozoite protein-142 vaccine
    Patent number: 7306806
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: December 11, 2007
    Assignee: United States of America as represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
  • Polypeptide from haemophilus influenza
    Patent number: 7291722
    Abstract: The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: November 6, 2007
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventor: Joelle Thonnard
  • Human protein kinases and uses therefor
    Patent number: 7288392
    Abstract: The invention relates to novel kinase nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: October 30, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, Rosana Kapeller-Libermann, Mark Williamson
  • Vaccines for infections
    Patent number: 7279171
    Abstract: Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 are provided. Nucleic acid vectors for the expression of MOMP polypeptides and MOMP polypeptide fusion proteins are disclosed. Nucleic acid vectors encoding a C. psittaci major outer membrane protein (MOMP) polypeptide lacking regions VD1 and VD2 useful for genetic, or “naked nucleic acid” vaccination are disclosed. Methods for preventing a Chlamydia psittaci infection in a subject using MOMP polypeptides, MOMP polypeptide-fusion proteins, or nucleic acid expression vectors are also provided.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: October 9, 2007
    Assignee: Board of Supervisors of Louisiana State University and Mechanical College
    Inventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, Abolgasem Baghian, Thomas N. Tully, Jr.
  • Detection of sarcocystis neurona
    Patent number: 7273709
    Abstract: A gene encoding a 29 kilodalton protein found on the surface of merozoite stage S. neurona has been cloned and sequenced. The protein encoded by this gene, termed SnSAG-1, is an immunodominant antigen recognized on protein blots. Methods for using nucleic acids and polypeptides relating to SnSAG-1 in diagnostic tests and vaccine development are disclosed.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: September 25, 2007
    Assignee: Univeristy of Florida Research Foundation, Inc.
    Inventors: John B. Dame, Siobhan P. Ellison, Charles A. Yowell
  • Vaccine and compositions for the prevention and treatment of neisserial infections
    Patent number: 7261901
    Abstract: The present invention is directed to novel polypeptides, polynucleotides and vaccines for use against Neisseria gonorrhoeae colonization or infection and/or Neisseria meningitidis colonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: August 28, 2007
    Assignee: University of Iowa Research Foundation
    Inventors: Michael A. Apicella, Jennifer L. Edwards
  • Recombinant merozoite protein-1vaccine
    Patent number: 7256281
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 14, 2007
    Assignees: United States of America as represented by the Secretary of the Army
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
  • Vaccine and compositions for the prevention and treatment of neisserial infections
    Patent number: 7250172
    Abstract: The present invention is directed to novel polypeptides, polynucleotides and vaccines for use against Neisseria gonorrhoeae colonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: July 31, 2007
    Assignee: University of Iowa Research Foundation
    Inventors: Michael A. Apicella, Jennifer L. Edwards, Bradford W. Gibson, Karoline Scheffler
  • Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use
    Patent number: 7241592
    Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 10, 2007
    Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.
    Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
  • Identification of cell surface proteins and their uses
    Patent number: 7241613
    Abstract: The invention provides for novel polypeptides of Candida species found on the cell wall of the Candida organism. The invention further provides for methods of using these polypeptides, the genes encoding the polypeptides and fragments thereof for preparing antibodies, vaccines, therapeutic and diagnostic compositions.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: July 10, 2007
    Assignee: Oscient Pharmaceuticals Corporation
    Inventors: Debra A. Willins, Arturo J. Morales, Guillaume Cottarel, Qiandong Zeng, Christina Alberti-Segui